Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor Article DOI:
Cite this article as: Maekawa, R., Maki, H., Wada, T. et al. Clin Exp Metastasis (2000) 18: 61. doi:10.1023/A:1026553414492 Abstract
The anti-metastatic efficacy and safety of a newly-developed matrix metalloproteinase (MMP) inhibitor were examined. MMI-166, a N-sulfonylamino acid derivative, inhibited the enzyme activity of MMP-2, 9, and 14 but not MMP-1, 3 or 7. Daily oral administration of MMI-166 resulted in potent inhibition of metastatic lung colonization of Lewis lung carcinoma injected via the tail vein and liver metastasis of C-1H human colon cancer implanted into the spleen at inhibition levels of 43% and 63%, respectively. Daily administration of MMI-166 also resulted in prolonged survival of mice given intraperitoneal implantation of Ma44 human lung cancer cells. The anti-metastatic activity of MMI-166 was as effective as that of other MMP inhibitors with broad inhibitory spectrum. MMI-166 did not affect
in vitro tumor cell growth. Neither body weight losses nor hematotoxicity was observed during long-term treatment, indicating the safety of MMI-166 in mice. These results indicate that the selective MMP inhibitor MMI-166 has therapeutic potential as an anti-metastasis agent. MMP MMP inhibitor anti-metastatic efficacy safety References
Yu AE, Herwitt RE, Connor EW, Stetler-Stevenson WG. Matrix metalloproteinases: Novel targets for directed cancer therapy. Drugs Aging 1997; 11: 229–44.
Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol 1990; 1: 99–106.
Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasiveness. Physiol Rev 1993; 73: 161–95.
Crowford HC, Matrisian LM. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 1994; 14: 234–45.
Jiang WG, Puntis MC, Hallett MB. Molecular and cellular basis of cancer invasion and metastasis: implications for treatment. Br J Surg 1994; 81: 1576–90.
MacDougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 1995; 14: 351–62.
Corcoran ML, Kleiner DE Jr, Stetler-Stevenson WG. Regulation of matrix metalloproteinases during extracellular matrix turnover. Adv Exp Med Biol 1995; 385: 151–9.
Ray JM, Stetler-Stevenson WG. Matrix metalloproteinases and malignant disease: recent development. Exp Opin Invest Drugs 1996; 5: 323–35.
Monteagudo C, Merino MJ, San-Juan J et al. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 1990; 136: 585–92.
Brown PD, Bloxodge RE, Stuart NSA et al. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung carcinoma. J Natl Cancer Inst 1993; 85: 574–8.
Rao JS, Steck PA, Mohanam S et al. Elevated levels of Mw 92,000 type IV collagenase in human brain tumors. Cancer Res 1993; 53: 2208–11.
Gress TM, Mueller-Pillash F, Lerch MM et al. Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407–13.
Liabakk N-B, Talbot I, Smith RA et al. Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type-IV collagenases in colorectal cancer. Cancer Res 1996; 56: 190–6.
Brown P. Matrix metalloproteinase inhibitors: a new class of anticancer agent. Curr Opin Invest Drugs 1993; 2: 617–26.
Beckett RP, Davidson AH, Drummond AH et al. Recent advances in matrix metalloproteinase inhibitor research. Drug Discovery Today 1996; 1: 16–26.
Talbot DC, Brown PD. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 1996; 32A: 2528–33.
Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs 1997; 15: 175–85.
White AD, Bocan TMA, Boxer PA et al. Emerging therapeutic advances for the development of second generation matrix metalloproteinase inhibitors. Curr Pharmaceutical Design 1997; 3: 45–58.
Rasmussen HS, McCann PP. Matrix metalloproteinase inhibitors as a novel anticancer strategy: A review with special focus on Batimastat and Marimastat. Pharmacol Ther 1997; 75: 69–75.
Sugita K. Recent advances in inhibitors of matrix metalloproteinases for cancer therapy. IDrugs 1999; 2: 327–39.
Wojotowicz-Praga S. Clinical potential of matrix metalloprotease inhibitors. Drugs R &; D 1999; 1: 117–29.
Tamura Y, Watanabe H, Nakatani T et al. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): Nsulfonylamino acid derivatives. J Med Chem 1998; 41: 640–9.
Maekawa R, Maki H, Yoshida H et al. Correlation of antiangiogenesis and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res 1999; 59: 1231–5.
Zook SE, Dagnino R Jr, Deason ME, Bender SL, Melnick MJ. PTC patent Application 1997; WO9720824.
Dickens JP, Crimmin MJ, Beckett RP. PCT patent Application 1994; WO9402447.
Ward RV, Hembry RM, Reynolds JJ, Murphy G. The purification of tissue inhibitor of metalloproteinase-2 from its 72 kDa progelatinase complex. Biochem J 1991; 278: 179–187.
Alley MC, Scudiero DA, Monks A et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1998; 48: 589–601.
Bradley TR and Metcalf D. The growth of mouse bone marrow cells in vitro. Aus J Exp Biol Med Sci 1966; 44: 287–99.
Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res 1980; 47: 1–9.
Dunnett CW. New tables for multiple comparisons with a control. Biometrics 1964; 20: 482–91.
Peto R, Peto J. Asymptotocally efficient rank invariant procedures. J R Stat Soc A 1972; 135: 185–207.
Uchida N, Kasai H, Takeda Y et al. Synergy of the combination of nedaplatin with etoposide in murine and human lung carcinoma. Anticancer Res 1998; 18: 247–52
Schultz RM, Silberman S, Persky B et al. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 1988; 48: 5539–45.
Kohka R, Zimmer MJ, Graham CH, Lala PK, Waterhouse P. Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J Natl Cancer Inst 1992; 84: 1017–22.
Bernhard EJ, Gruber SB, Muschel RJ. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase / collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 1994; 91: 4293–7.
Davis B, Brown PD, East N et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53: 2087–91.
Naito K, Kanbayashi N, Nakajima S et al. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int J Cancer 1994; 58: 730–5.
Chirivi RGS, Garofalo A, Crimmin MJ et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994; 58: 460–4.
Wang X, Fu X, Brown PD et al. Martix metalloprotenase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994; 54: 4726–8.
Watson SA, Morris TM, Robinson G et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor Batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55: 3629–33.
Conway JG, Trexler SJ, Wakefield JA et al. Effect of matrix metalloproteinaseinhibitors on tumor growth and spontaneous metastasis. Clin Exp Metastasis 1996; 14: 115–24.
Santos O, MeDermott CD, Daniels RG, Appelt K. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin ExpMetastasis 1997; 15: 499–508.
Hutchinson JW, Tierney GM, Parson SL, Davis TRC. Dupuytren’s disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg 1998; 80: 907–8.
Itoh T, Tanioka M, Yoshida H et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 1048–51.
Itoh T, Tanioka M, Matsuda H et al. Experimental metastasis is suppressed in MMP-9 deficient mice. Clin Exp Metastasis 1999; 17: 177–81.
Google Scholar Copyright information
© Kluwer Academic Publishers 2000